We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arix Bioscience Plc | LSE:ARIX | London | Ordinary Share | GB00BD045071 | ORD 0.001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 142.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Arix Bioscience PLC (ARIX) Unaudited NAV for March 2023 17-Apr-2023 / 07:00 GMT/BST
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Unaudited NAV for March 2023
LONDON, 17 April 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value ("NAV") of the Company for the date ended 31 March 2023 as follows:
Hot Features
Premium
NAV Breakdown
Date Total NAV
Listed Portfolio Unlisted Portfolio Cash Other Interests NAV per share
31 March 2023
GBP42.9m GBP66.6m GBP108.7m GBP3.1m GBP221.3m GBP1.71
(unaudited)
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071 Category Code: MSCL TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 237106 EQS News ID: 1608427 End of Announcement EQS News Service =------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1608427&application_name=news
(END) Dow Jones Newswires
April 17, 2023 02:00 ET (06:00 GMT)
1 Year Arix Bioscience Chart |
1 Month Arix Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
